文献速递瓣膜外科

微创主动脉瓣修复二十年经验

Twenty Years' Experience With Minimally Invasive Aortic Valve Repair.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

本文报道单中心2000至2022年308例经上半胸骨小切口行微创主动脉瓣修复(MIAVr)患者的长期结果,中位年龄56岁,25.9%为女性。中转胸骨切开3例(1%),围术期卒中1例(0.3%),30天死亡率0.3%。随访再手术累积发生率5年4.1%、10年11.7%、15年15.8%,提示MIAVr安全可重复且不损害长期瓣膜耐久性。

要点

  • MIAVr经上半胸骨小切口可行,30天死亡率0.3%、围术期卒中0.3%。
  • 再手术累积发生率5年4.1%、10年11.7%、15年15.8%。
  • 微创入路不损害主动脉瓣修复的长期耐久性与瓣膜性能。

核心结论

  • MIAVr安全、可重复,长期瓣膜性能良好,微创入路不损害AVr后的长期耐久性。

研究设计与样本

  • 单中心回顾性队列,2000至2022年共308例经上半胸骨小切口行MIAVr,中位年龄56(20-83)岁,25.9%为女性,随访采用Kaplan-Meier与竞争风险分析。

主要发现

  • 中转胸骨切开3例(1%),围术期卒中1例(0.3%),30天死亡率0.3%。
  • 随访期间29例需主动脉瓣再手术,再手术累积发生率5年4.1%(95%CI 2.4%-7.2%)、10年11.7%(95%CI 8.3%-16.3%)、15年15.8%(95%CI 11.5%-21.4%)。
  • 复发AR≥中度的累积发生率5年12.1%(95%CI 9.2%-16.0%)、10年18.7%(95%CI 15.0%-23.2%)、15年23.0%(95%CI 18.8%-28.1%)。
  • 总体生存率5年90.7%(95%CI 87.2%-94.2%)、10年79.3%(95%CI 73.8%-85.1%)、15年63.4%(95%CI 53.9%-74.7%)。

临床怎么用

  • 在经验丰富的中心,对主动脉瓣关闭不全患者可考虑经上半胸骨小切口的MIAVr,并需长期随访再手术与复发AR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Aortic valve repair (AVr) has become the preferred strategy to treat patients with significant aortic valve incompetence at experienced centres. Minimally invasive AVr (MIAVr) has not yet been widely adopted due to its higher technical complexity; thus, we aim to present our long-term results. METHODS: From 2000 to 2022, 308 patients with a median age of 56 (20-83) years (25.9% female) received MIAVr through upper ministernotomy. Follow-up data were evaluated using Kaplan-Meier and competing risk analysis. RESULTS: Conversion to sternotomy was required in 3 patients (1%), and 1 patient (0.3%) suffered a perioperative stroke. Thirty-day mortality was 0.3%. During follow-up, 29 patients required aortic valve reoperation. The cumulative incidence of reoperation was estimated at 4.1% (95% CI, 2.4%-7.2%) at 5 years, 11.7% (95% CI, 8.3%-16.3%) at 10 years, and 15.8% (95% CI, 11.5%-21.4%) at 15 years. The overall estimated cumulative incidence of recurrent AR ≥ moderate was 12.1% (95% CI, 9.2%-16.0%) at 5 years, 18.7% (95% CI, 15.0%-23.2%) at 10 years, and 23.0% (95% CI, 18.8%-28.1%) at 15 years. The estimated overall survival was 90.7% (95% CI, 87.2%-94.2%) at 5 years, 79.3% (95% CI, 73.8%-85.1%) at 10 years, and 63.4% (95% CI, 53.9%-74.7%) at 15 years. CONCLUSIONS: MIAVr is safe and reproducible with very good long-term valve performance. Minimally invasive access does not compromise long-term durability and valve performance after AVr.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Salem R, Rashid H, Karimian-Tabrizi A, et al. Twenty Years' Experience With Minimally Invasive Aortic Valve Repair. Eur J Cardiothorac Surg. 2025. PMID: 40880306. doi:10.1093/ejcts/ezaf294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。